Researchers have found that psilocybin, which is the hallucinogenic compound found in so-called magic mushrooms, has shown potential in treating various mental conditions, including anxiety, major depressive disorder and addiction.
A woman in Newfoundland who was diagnosed with severe PTSD revealed that psilocybin helped get her life back. The woman, whose identity remains withheld, stated that after her diagnosis, conventional medications and therapies helped for a while, but she eventually became resistant to them. When her sleep and anxiety became worse, she went to a psilocybin psychotherapy retreat in Jamaica where the substance is legal.
She gave an account of her experience, explaining that during the retreat, health-care professionals were present at all times, monitoring each patient while they were using psilocybin. She noted that every psychedelic trip was followed by intense group therapy, which she asserted helped her get through the barriers that had been holding her back.
Now, the woman microdoses using capsules, which she says don’t get her high but do make her calm. She’s a member of the Psychedelic Society of Newfoundland and Labrador, which was established earlier in April of this year by Brandon Batstone.
Batstone stated that the objective of the society was to create a safe space for individuals to be open about their experiences as it was hard for individuals to do so given that most of these substances are illegal. Batstone revealed that he believed in using psychedelics as they helped him overcome drug addiction. He noted that he wasn’t trying to convince people to use these substances. Instead, the aim of the society is to educate people, making them aware of these substance’s benefits and change their perspectives.
The John Hopkins Center for Psychedelic and Consciousness Research is the largest center for psychedelic studies in the world. It conducts research on substances such as psilocybin, MDMA and ketamine as experimental treatments for Alzheimer’s, post-traumatic stress disorder and depression.
A separate University of Toronto psychedelics research program is expecting approval from Health Canada, which will allow them to conduct microdosing research on psilocybin.
Scientific evidence on the therapeutic use of psychedelics has been growing as more institutions conduct studies on the substances. However, experts believe that despite this progress, we have a long way to go before the use of psychedelics becomes a part of mainstream health care. In the meantime, individuals are advised to stay clear of these substances unless under the supervision of experienced and licensed healthcare providers, such as during clinical trials or in jurisdictions where psychedelic-assisted therapy is legal.
With companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) engaged in psychedelic-based medicine development, opportunities for participating in clinical trials could soon present themselves to those interested.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.